Elanco Animal Health Incorporated announced on June 12, 2025, that Zenrelia (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP). This recommendation paves the way for the product's marketing authorization in the European Union within the next 60 days.
The CVMP's positive opinion acknowledges Zenrelia's efficacy in treating pruritus associated with allergic dermatitis and clinical manifestations of atopic dermatitis in dogs. Elanco expects the EU label to be consistent with other markets outside the United States where the product has already been approved.
Dr. Ellen de Brabander, Executive Vice President Innovation and Regulatory Affairs at Elanco, highlighted this as a significant advancement for Zenrelia, noting it is Elanco's fastest globalized product with eight major regulatory approvals expected in just 18 months. Elanco anticipates launching the product shortly after receiving marketing authorization, with supply in the marketplace before the end of the third quarter.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.